Metformin Synergizes with PD-L1 Monoclonal Antibody Enhancing Tumor Immune Response in Treating Non-Small Cell Lung Cancer and Its Molecular Mechanism Investigation

Despite non-small cell lung cancer (NSCLC) treatment is proved to be effective using PD-L1 monoclonal antibody (PD-L1 MAb), it is commonly seen in immune-related adverse events reported. We aimed to explore metformin synergized with PD-L1 MAb in treating NSCLC and its potential molecular mechanism....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yifan, Hu, Jingguo, Sun, Yu, Song, Bo, Zhang, Yan, Lu, Yusong, Ma, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527407/
https://www.ncbi.nlm.nih.gov/pubmed/36199547
http://dx.doi.org/10.1155/2022/5983959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527407/
https://www.ncbi.nlm.nih.gov/pubmed/36199547
http://dx.doi.org/10.1155/2022/5983959

Ejemplares similares